TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 60 to 85 years on the day of inclusion~* Informed consent form signed~* Able to attend all scheduled visits and to comply with all trial procedures.~Exclusion Criteria:~* Systemic hypersensitivity to egg proteins, chick proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances~* Febrile illness (oral temperature \>= 37.5°C equivalent rectal temperature \>= 38.0°C) on the day of inclusion~* Any vaccination or participation in another clinical trial in the four weeks preceding the first trial vaccination~* Planned participation in another clinical trial during the present trial period~* Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy~* Chronic illness at a stage that could interfere with trial conduct or completion~* Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures~* Blood or blood-derived products received in the past three months~* Vaccination planned in the four weeks following the first trial vaccination~* Previous vaccination against influenza (in the previous six months) with the trial vaccine or another vaccine~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination~* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old.~* Confirmed HIV-1 uninfected.~* Willing to provide screening informed consent~* Currently pregnant~* Considered high risk for HIV infection~  * Unprotected sex during pregnancy~ * HIV status of current sexual partner is positive or unknown~* Results of Hepatitis B Virus (HBV) screening (HBsAg testing) available from specimen obtained within 30 days prior to entry~* Plans to deliver in the study affiliated hospital~* Has no plans to move residence outside of the catchment area during the 18 months following delivery~Exclusion Criteria:~* HIV infected~* \<18 years of age~* The following laboratory values from a specimen obtained within 30 days prior to study entry:~  * Hemoglobin \<9.5 g/dL~ * White Blood Cell Count (WBC) \< 1500 cells/mm3~ * Absolute Neutrophil Count (ANC) \< 750 cells/mm3~ * Platelets \< 100,000 cells/mm3~ * Alanine Aminotransferase (ALT) \> 2.5 x upper limit of normal (ULN)~ * Estimated creatinine clearance of \< 70 ml/min using the cockcroft-gault equation for women: {(\[140 - age (years)\] x \[weight (kg)\]) ÷ \[72 x serum Cr (mg/dL)\]} x 0.85~ * Hepatitis B surface antigen (HBsAg) positive~* Participation in any other study~* In labour - at onset or beyond~* Serious illness (including TB) and/or hospitalization~* Receipt of TB treatment within 30 days prior to study entry~* Fetus detected with serious congenital malformation (ultrasound not required to rule out this condition)~* History of documented structural or conduction heart defect~* Social or other circumstances which would hinder long-term follow-up, in the opinion of the site investigator~* Currently incarcerated~* Substance or alcohol abuse (a score of \>8 on the WHO Alcohol Use).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Intervention - Truvada) (Type: ACTIVE_COMPARATOR): Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
- Arm B (Control - Standard of Care) (Type: NO_INTERVENTION): Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ASD less than or equal to 17 mm.~Exclusion Criteria:~* Conditions that would confound treatment of ASD or complicate distinguishing onset of adverse events.~* Unable to accommodate device delivery catheter.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Device (Type: EXPERIMENTAL): ASD closure with the GORE® CARDIOFORM Septal Occluder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 18 years of age~* Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit~* Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale~* Subject is a candidate for systemic PSO therapy and/or phototherapy~* Female subject of child bearing potential must be willing to use highly effective method of contraception~Exclusion Criteria:~* Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic, recurrent, or chronic infections~* Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection~* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection~* Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study~* Presence of active suicidal ideation or positive suicide behavior~* Presence of moderately severe major depression or severe major depression~* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab cohort (Type: EXPERIMENTAL): Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
- Bimekizumab Escape arm (Type: EXPERIMENTAL): Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed chronic genotype 1 or 3 HCV infection~* HCV treatment-naive~* Individuals will have cirrhosis status assessment; liver biopsy may be required.~* Screening laboratory values within predefined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Contraindication to ribavirin therapy~* Excessive alcohol ingestion as defined by protocol~* History of solid organ transplantation~* Current or prior history of clinical hepatic decompensation~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV 16 Weeks (Type: EXPERIMENTAL): SOF+RBV for 16 weeks
- SOF+RBV 24 Weeks (Type: EXPERIMENTAL): SOF+RBV for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~• Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C~Exclusion Criteria:~* Refusal or inability to sign informed consent for the trial~* Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires~* BMI ≥ 40 or \< 18~* Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial~* Women who are pregnant or lactating~* Diagnosis of IBS-D or IBS-M~* Organic or obstructive disease of the small or large intestine~* Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)~* Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication~* Unstable medical illness~* Bilirubin \> 3X ULN in the absence of a conjugation defect~* Any laboratory value \> 3X ULN unless discussed and approved by the study Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 3.0 mg plecanatide (Type: ACTIVE_COMPARATOR): Plecanatide 3.0 mg dosed daily for 12 weeks
- 6.0 mg plecanatide (Type: ACTIVE_COMPARATOR): Plecanatide 6.0 mg dosed daily for 12 weeks
- Matching placebo (Type: ACTIVE_COMPARATOR): Placebo dosed daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* A minimum of 6 months documented history of asthma according to the JGL2006/GINA2006 definition~* FEV1\> 70% of predicted normal value pre-bronchodilator~Exclusion Criteria:~* Having a known or suspected allergy to study therapy (active drugs or additive)~* Having a known clinical history of hypertension, relevant arrhythmias or other heart disease, eg, ischemic heart disease, cardiomyopathy, valvular heart disease, or heart failure~* Having been treated with oral, parenteral or rectal glucocorticoids within 4 weeks, or with depot parenteral glucocorticoids within 3 months~* Respiratory infection significantly affecting the asthma, as judged by the investigator within 4 weeks

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- First Symbicort, then Terbutaline (Type: EXPERIMENTAL): Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
- First Turbuhaler, then Symbicort (Type: EXPERIMENTAL): Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients fulfilling the following criteria at Screening are eligible for participation in the study:~1. Age 13 years or older~2. Laboratory confirmed diagnosis of HAE~3. A history of frequent HAE attacks (at least 4 attacks per month across a minimum of 3 consecutive months).~4. Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception.~5. Provided written informed consent (and written assent for minors)~6. Willingness and ability to comply with all protocol procedures~Exclusion Criteria:~Patients who meet any of the following criteria at Screening are to be excluded from study participation:~1. Patients with medical history of allergy to rabbits or rabbit-derived products (including rhC1INH)~2. Diagnosis of acquired angioedema (AAE)~3. Patients who are pregnant, or breastfeeding, or are currently intending to become pregnant~4. Treatment with any investigational drug in the past 30 days~5. Patients with any condition or treatment that, in the opinion of the Investigator, might interfere with the evaluation of study objectives~6. Patients currently treated with angiotensin-converting enzyme (ACE) inhibitors

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhC1INH twice weekly (Type: EXPERIMENTAL): rhC1INH administered twice weekly
- rhC1INH once weekly (Type: EXPERIMENTAL): rhC1INH administered once weekly
- Placebo (Saline) twice weekly (Type: PLACEBO_COMPARATOR): Placebo (Saline) administered twice weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18-55 with a primary diagnosis of nonpsychotic MDD~Exclusion Criteria:~* History of non-response to multiple antidepressants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Antidepressant + SPD489
- Placebo (Type: PLACEBO_COMPARATOR): Antidepressant + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years at the time of signing informed consent~* Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening~* HbA1c (glycosylated haemoglobin) 7.0-10.0% \[53mmol/mol-86mmol/mol\] (both inclusive) by central laboratory analysis~* Current treatment with IGlar (insulin glargine) for at least 90 calendar days prior to screening~* Stable daily dose of IGlar between 20 units and 50 units (both inclusive) for at least 56 calendar days prior to screening. Individual fluctuations of plus/minus 10% within the 56 calendar days prior to screening are acceptable, however on the day of screening total daily dose should be within the range of 20 units-50 units both inclusive~* Stable daily dose of metformin (at least 1500 mg or max tolerated dose) for at least 90 calendar days prior to screening~* Body mass index (BMI) below or equal to 40 kg/m\^2~Exclusion Criteria:~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 calendar days before screening~* Anticipated initiation or change in concomitant medications in excess of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids)~* Impaired liver function, defined as alanine aminotransferase (ALT) at least 2.5 times upper limit of normal~* Renal impairment eGFR (electronic case report form) below 60 mL/min/1.73 m\^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)~* Screening calcitonin at least 50 ng/L~* History of pancreatitis (acute or chronic)~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegLira (Type: EXPERIMENTAL): None
- IGlar plus IAsp (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent, age-adapted~* Male or female aged 1 to 70 years~* Diagnosis of primary humoral immunodeficiency~* No prior immunoglobulin substitution therapy~* IgG level of \<5 g/L at screening~* Women of childbearing potential must use medically approved contraception and must have a negative urine pregnancy test at screening~Key Exclusion Criteria:~* Evidence of serious infection between screening and first treatment~* Bleeding disorders that require medical treatments~* Any medical disorder causing secondary immune disorders, autoimmune neutropenia, or a clinically significant defect in cell mediated immunity~* Any condition likely to interfere with evaluation of the study drug or satisfactory conduct of the trial

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vivaglobin (Type: EXPERIMENTAL): Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent;~* Bipolar disorder with most recent episode depressed;~* Outpatient status~Exclusion Criteria:~* Patients with a current Axis I disorder other than bipolar disorder within 6 months of screening;~* Patients whose current episode of depression exceeds 12 months or is less than 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete